Document is current
Any future updates will be listed below
-
Authors
Judson, Matthew C.
de Almeida, Luis Pereira
Burdine, Rebecca D.
Chamberlain, Stormy J.
Deverman, Benjamin E.
Distel, Ben
Ehlers, Michael D.
Jalazo, Elizabeth
Kushner, Steven A.
Nespeca, Mark
Sanders, Stephan J.
Scheffner, Martin
Yi, Jason J.
Zylka, Mark J.
Elgersma, Ype
Philpot, Benjamin D.
-
Funding
Funding for this research was provided by:
Angelman Syndrome Foundation
Angelman Syndrome Alliance
- License Information
-
More Information
Article History
Received: 16 September 2025
Accepted: 23 February 2026
First Online: 7 March 2026
Declarations
:
: MDE is an employee of MPM BioImpact, CEO and shareholder of Ascidian Therapeutics and Rhodes Therapeutics, and Board Member and shareholder of Aulos Bioscience, Replicate Bioscience, Orna Therapeutics, and Reunion Neuroscience. MN receives financial compensation from Ionis Pharmaceuticals as a member of an Independent Safety Monitoring Committee for clinical trials of an ASO therapy in Angelman syndrome. BED is a scientific founder of Apertura Gene Therapy. SJC is an employee of F. Hoffmann-La Roche. EJ has received financial compensation from Ionis Pharmaceuticals for participation in an advisory board. BDP is a consultant for Astellas Gene Therapies and has sponsored research agreements with Denali Therapeutics, Ionis Pharmaceuticals, Arbor Biotechnologies, Gondola Bio, and Mahzi Therapeutics. YE is a consultant for Astellas Gene Therapies and has sponsored research agreements with Hoffmann-La Roche, Ionis Pharmaceuticals, and Gondola Bio.
